-
admin
Posts
Optellum Secures TGA Approval to Expand AI-Enabled Lung Nodule Solution To Australia
OXFORD, England, Feb. 27, 2026 /PRNewswire/ — Optellum, the leading AI-enabled solution for earlier lung cancer detection, is thrilled to announce that it has received...
Cut the Cupcakes. Rebecca Moulynox on What Women Really Want at Work
As the 2026 Best Workplaces for Women Australia List set to drop, Great Place To Work’s GM has thoughts on International Women’s Day, performative targets...
Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial
Highlights: First participant enrolled and dosed with NUZ-001 in Regimen I of the HEALEY ALS Platform Trial evaluating NUZ-001 for the treatment of ALS Approximately...
dsm-firmenich cancels its shares following completion of its €1.08 billion share repurchase program
Press Release dsm-firmenich cancels its shares following completion of its €1.08 billion share repurchase program Kaiseraugst (Switzerland), Maastricht (Netherlands), February 26 2026 dsm-firmenich, innovators in...
Amphista Therapeutics presents new data demonstrating how its advanced Eclipsys® platform is delivering Targeted Glue™ degraders using novel E3 ligases into the clinic
Presentation showcases how Amphista’s Eclipsys® platform is enabling the development of Targeted Glue™ degraders, which recruit diverse E3 ligases, describing for the first time the...
Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026
– New analyses of efficacy endpoints from the Phase 2 VIBRANT trial of verekitug in CRSwNP to be presented during the late-breaking poster session –...
TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03
Completed enrollment of Cohort C in the Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing process Received FDA clearance of INDs for TSC-102-A01 and...
BioCryst Reports Full Year 2025 Financial Results and Provides Business Update
—Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the European ORLADEYO business...
Juvenescence successfully completes Phase 1 clinical trial of PAI-1 inhibitor and strengthens clinical development leadership
PAI-1 Inhibitor (MDI-2517) demonstrates good safety and tolerability profile, with Phase 2 proof-of-concept trial planned for 2026 in patients with metabolic and fibrotic disease Carmel...
Arhaus Reports Fourth Quarter and Full Year 2025 Financial Results; Announces Special Cash Dividend
BOSTON HEIGHTS, Ohio, Feb. 26, 2026 (GLOBE NEWSWIRE) — Arhaus, Inc. (“Arhaus” or the “Company”) (NASDAQ: ARHS), a premium home furnishing brand known for responsibly...
